Titre :
  • Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial.
Auteur : Ingle, James N ; Tu, Dongsheng ; Pater, Joseph L ; Martino, S ; Robert, Nicholas J ; Muss, Hyman B ; Piccart-Gebhart, Martine ; Castiglione, Monica ; Shepherd, L ; Pritchard, Kathleen ; Livingston, Robert ; Davidson, Nancy E ; Norton, Larry ; Perez, Edith A ; Abrams, Jeffrey S ; Cameron, David A ; Palmer, Michael J ; Goss, Paul E
Informations sur la publication : Breast cancer research and treatment, 99, 3, (page 295-300)
Statut de publication : Publié, 2006-10
Sujet CREF : Sciences bio-médicales et agricoles
Mots-clés : Adjuvant hormonal therapy
Early breast cancer
Mots-clés MeSH : Aged
Antineoplastic Agents -- administration & dosage
Antineoplastic Agents -- therapeutic use
Aromatase Inhibitors -- administration & dosage
Aromatase Inhibitors -- therapeutic use
Breast Neoplasms -- chemistry
Breast Neoplasms -- drug therapy
Breast Neoplasms -- mortality
Breast Neoplasms -- pathology
Chemotherapy, Adjuvant
Disease-Free Survival
Double-Blind Method
Drug Administration Schedule
Female
Humans
Middle Aged
Nitriles -- administration & dosage
Nitriles -- therapeutic use
Postmenopause
Proportional Hazards Models
Receptors, Estrogen -- analysis
Receptors, Progesterone -- analysis
Selective Estrogen Receptor Modulators -- therapeutic use
Survival Analysis
Tamoxifen -- therapeutic use
Time Factors
Treatment Outcome
Triazoles -- administration & dosage
Triazoles -- therapeutic use
Note : Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langue :
  • Anglais
Identificateurs : urn:issn:0167-6806 
info:doi/10.1007/s10549-006-9207-y
info:pmid/16541302